Business brief
Defense Inflows and Specialty Pharma Reshape Corporate Israel
Private equity inflows into defense suppliers and key FDA clearances for Teva underscore an aggressive push into high-margin foreign contracts.
Business
FDA approval for Weltruza confirms Teva's turnaround is working — high-margin neuroscience drugs are finally offsetting years of generic price decay.
BackgroundTeva spent years managing a crushing debt load and steep price declines following its $40 billion acquisition of Actavis in 2016. The company partnered with French biotech MedinCell to engineer extended-release formulations that eliminate post-injection delirium complications.
- Weltruza marks Teva's second commercial product using MedinCell's copolymer delivery platform, following the steady market rollout of Uzedy.
- The subcutaneous injection delivers continuous therapeutic olanzapine for up to two months, removing the mandatory post-injection hospital observation periods that hobbled older formulations.
- Branded neuroscience therapies deliver substantially higher gross margins than legacy generics, accelerating Teva's earnings recovery across Wall Street and Tel Aviv.
Business
CVC bought into Fibrotex at a $900M valuation — NATO armies urgently need advanced multispectral camouflage to protect ground units from drone reconnaissance.
BackgroundPetah Tikva-based Fibrotex manufactures signature-management fabrics that conceal armored vehicles and troops from thermal optics and radar sensors. Global defense spending has surged following the war in Ukraine, driving Western armed forces to modernize battlefield concealment against modern sensor suites.
- The transaction values Fibrotex at nearly $900 million after competitive bidding run by Jefferies, cementing its transition from a domestic supplier into an international prime contractor.
- Fibrotex booked up to $150 million in 2025 revenue with double-digit growth projected, supported by multi-year procurement frameworks across Europe and North America.
- The US Army and European militaries rely on Fibrotex materials to shield mobile command posts, countering Russian and Iranian reconnaissance drones on contested fronts.
Business
De Beers returned to Tel Aviv for predictable tax rules — a crucial win that keeps the Ramat Gan bourse competitive against Antwerp and Dubai.
BackgroundIsrael was long a premier cutting and trading capital for rough gems, but restrictive corporate taxation prompted many local dealers to shift transactions overseas. Concurrently, cheap lab-grown alternatives have battered natural diamond prices, forcing legacy traders to lower operational overhead.
- The new tax protocol fixes turnover levies through 2028, cutting corporate compliance friction and restoring predictability for domestic diamond merchants.
- Tel Aviv's zero-duty regime gives local diamantaires a cost edge over Dubai's 5% customs levy and Belgium's heavier turnover tax burdens.
- De Beers restarted local auctions while natural rough prices languish near $105 per carat, squeezed by rapid consumer adoption of synthetic lab-grown alternatives.
Business
Bagira leveraged its record Tel Aviv listing into a European offensive — mid-tier simulation specialists can now outmaneuver traditional aerospace giants for defense training contracts.
BackgroundBagira designs tactical combat simulators and computerized marksmanship ranges that prepare infantry units for urban combat without consuming live ordnance. European armed forces have ramped up simulation spending to rapidly train fresh recruits while conserving munitions reserves depleted by aid to Ukraine.
- Bagira's listing represents the largest defense initial public offering in the history of the Tel Aviv Stock Exchange, reflecting intense investor appetite for military technology.
- First-half revenue rose 51% to ₪163 million on surging European training contracts, demonstrating strong foreign demand for digitized warfare drills.
- Net profit jumped 45% to ₪54 million as frontline militaries turned to virtual simulations to stretch strained ammunition stockpiles.
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
